The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL).
 
Craig Steven Sauter
Consulting or Advisory Role - Juno Therapeutics; Spectrum Pharmaceuticals
 
Isabelle Riviere
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Research Funding - Juno Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics
 
Yvette Bernal
No Relationships to Disclose
 
Xiuyan Wang
No Relationships to Disclose
 
Terence Purdon
No Relationships to Disclose
 
Sarah Yoo
No Relationships to Disclose
 
Craig H. Moskowitz
No Relationships to Disclose
 
Sergio Giralt
No Relationships to Disclose
 
Matthew J. Matasar
No Relationships to Disclose
 
Kevin Joseph Curran
No Relationships to Disclose
 
Jae Hong Park
Research Funding - Juno Therapeutics (Inst)
 
Michel Sadelain
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Renier J. Brentjens
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics